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A
 
BSTRACT
 
Atopic disorders, such as asthma, eczema and rhinitis,
develop due to the interactions between genetic
and environmental factors. Atopy is characterized by
enhanced IgE responses to environmental antigens.
The production of IgE is upregulated by Th2 cytokines,
in particular interleukin (IL)-4, and downregulated by
Th1 cytokines, in particular interferon (IFN)-
 
γ
 
. In the
present review, we present the genetic factors respon-
sible for IgE production and genetic defects in the
downregulation (brake) of IgE production, especially
in terms of IL-12 and IL-18 signaling, mutations of
the IL-12 receptor 
 
β
 
2 chain gene and mutations of the
IL-18 receptor 
 
α
 
 chain gene in atopy. Moreover, we
newly present a genetic classification of atopy. There
are four categories of genes that control the expression
of allergic disorders, which include: (i) antigen recog-
nition; (ii) IgE production (downregulation = brake;
and upregulation); (iii) the production and release of
mediators; and (iv) events on target organs. In the
near future, this genetic classification will facilitate
the development of tailor-made treatment.
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I
 
NTRODUCTION
 
Atopic disorders, such as asthma, eczema and rhinitis,
develop due to the interactions between genetic and
environmental factors. Atopy is characterized by
enhanced IgE responses to environmental antigens. The
production of IgE is upregulated by Th2 cytokines, in
particular interleukin (IL)-4, and is downregulated by Th1
cytokines, in particular interferon (IFN)-
 
γ
 
.
 
1
 
 Interleukin-12,
which is a cytokine that promotes cell-mediated Th1
responses and the production of IFN-
 
γ
 
, is one of the
important cytokines that downregulates IgE production.
Interleukin-18, originally known as an IFN-
 
γ
 
-inducing
factor, is a recently cloned cytokine of approximately
18 kDa secreted by Kupffer cells of the liver and
activated macrophages.
 
2
 
 Interleukin-18 strongly aug-
ments IFN-
 
γ
 
 production by T lymphocytes, natural killer
(NK) cell cytotoxicity and T lymphocyte proliferation.
In the present review, we discuss the genetic factors
responsible for IgE production and the genetic defects in
the downregulation (brake) of IgE production in atopy.
Moreover, we newly present a genetic classification of
atopy.
 
D
 
EVELOPMENT
 
 
 
OF
 
 
 
ALLERGIC
 
 
 
DISEASES
 
A questionnaire was distributed in March 1991 to
children under 16 years of age who were attending
kindergarten or elementary or junior high school in two
Japanese cities, namely Gifu, with a temperate climate,
and Itoman, with a subtropical climate. The number
of subjects analyzed was 1243 in Gifu and 1953 in
Itoman. Multiple logistic regression analysis was per-
formed using SAS (SAS Institute, Cary, NC, USA).
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Multiple logistic regression analysis showed that, in both
cities, children of families with a history of allergy have a
significantly higher risk (relative risk 3.58 and 4.22 for
Gifu and Itoman, respectively) of contracting an allergic
disease (Table 1). These results show that there is a
genetic accumulation in the development of allergic
disorders. Therefore, the development of allergic dis-
orders is correlated with some genes. We think that
multiple causative genes, but not a single gene, are
correlated, because there are multiple pathogeneses of
allergic reactions.
 
G
 
ENETIC
 
 
 
FACTORS
 
 
 
OF
 
 
 
ENHANCED
 
 
 
IGE
 
 
 
PRODUCTION
 
 
 
AND
 
 
 
ATOPY
 
Serum IgE levels of atopic children were plotted against
serum IgE levels of their parents (Fig. 1) and a good
correlation was found (
 
P
 
 < 0.016). Therefore, this indi-
cates that IgE production shows genetic accumulation.
 
3
 
Several linkage analyses and mutations for candidate
genes of atopy (i.e. enhanced IgE production) have been
reported. In 1989, Cookson 
 
et al
 
.
 
4
 
 reported a linkage
between IgE responses underlying asthma and rhinitis
and chromosome 11q. Moreover, Shirakawa 
 
et al
 
.
 
5
 
Table 1
 
Genetic and environmental factors in relation to any allergic diseases as analyzed by multiple logistic regression
Independent variables Relative risk (95% confidence interval) 
Gifu (
 
n
 
 = 1243) Itoman (
 
n
 
 = 1953)
Family history
No 1 1
Yes 3.58 (2.17–5.91) 4.22 (2.91–6.12)
Sex
Male 1 1
Female 0.93 (0.69–1.27) 0.60 (0.45–0.79)
Age (years)
0–3 1.72 (0.87–3.40) 0.70 (0.27–1.82)
4–6 1.47 (0.93–2.31) 0.80 (0.44–1.46)
7–9 1.30 (0.81–2.07) 1.10 (0.75–1.62)
10–12 1.15 (0.71–1.85) 1.06 (0.72–1.56)
13–15 1 1
Structure of house
Made of wood 1 1
Made of reinforced concrete 1.22 (0.87–1.72) 1.15 (0.75–1.78)
Apartment house 1.27 (0.66–2.42) 0.94 (0.60–1.48)
Flooring
Wooden floor 1 1
Tatami 0.98 (0.64–1.49) 1.91 (1.08–3.38)
Carpet on tatami 1.17 (0.79–1.72) 1.65 (0.75–3.63)
Carpet on wooden floor 2.00 (1.17–3.42) 1.71 (0.91–3.23)
Pets
No 1 1
Yes 0.88 (0.62–1.23) 0.81 (0.58–1.14)
 
Fig. 1
 
Relationship between serum total IgE levels of atopic
children and the IgE levels of their parents (the highest IgE level
of two spouses was used). Children older than 6 years were
selected. 
 
y
 
 = 1.38 + 0.3461
 
x
 
; 
 
P
 
 < 0.016.
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reported that a common variant of the 
 
β
 
-subunit of the
high-affinity IgE receptor (Fc
 
ε
 
RI
 
β
 
) on chromosome 11,
Ile181Leu within the 4th transmembrane domain, shows
significant association with positive IgE responses.
Several associations have been noted between atopy
and genes on the chromosome 5 cytokine cluster,
including IL-4.
 
6,7
 
 In 1998, Mitsuyasu 
 
et al
 
.
 
8
 
 reported that
the Ile50Val variant of the IL-4 receptor 
 
α
 
 (IL-4R
 
α
 
) chain
upregulates IgE synthesis and is associated with atopic
asthma. Moreover, Shirakawa 
 
et al
 
.
 
9
 
 noted genetic
variants of IL-13. Very recently, we found that reduced
IFN-
 
γ
 
 production by peripheral blood mononuclear cells
(PBMC) following stimulation with IL-12 or IL-18 is
associated with heterozygous IL-12 receptor 
 
β
 
2 (IL-12R
 
β
 
2)
chain gene or IL-18 receptor 
 
α
 
 (IL-18R
 
α
 
) chain gene
mutations in atopic subjects.
 
10,11
 
G
 
ENETIC
 
 
 
DEFECTS
 
 
 
IN
 
 
 
THE
 
 
 
DOWNREGULATION
 
 
 
OF
 
 
 
IGE
 
 
 
PRODUCTION
 
 
 
IN
 
 
 
ATOPY
 
The production of IgE is upregulated by Th2 cytokines, in
particular IL-4, and is downregulated by Th1 cytokines,
in particular IFN-
 
γ
 
.
 
1
 
 Interleukin-12 and IL-18 are the
important cytokines that induce IFN-
 
γ
 
 and downregulate
IgE production (Fig. 2).
In this section, the genetic defects in the down-
regulation (brake) of IgE production, especially, in terms
of IL-12 and IL-18 signaling, are discussed.
 
Interleukin-12 and IL-12R
 
Interleukin-12, which is produced by activated antigen-
presenting cells, is a cytokine that consists of two
disulfide-linked subunits, p35 and p40. Interleukin-12
 
Fig. 2
 
The Th1 and Th2 lymphocyte balance and upregulation and downregulation of IgE production. IL, interleukin; DH, delayed-
type hypersensitivity; IFN, interferon; APC, antigen-presenting cell; HLA, human leukocyte antigen; TCR, T cell receptor; Baso,
basophils; Mast, mast cells; Eo, eosinophils.
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plays a central role in promoting Th1-type immune
responses and, thus, cell-mediated immunity.
 
12–15
 
 Inter-
leukin-12 also induces IFN-
 
γ
 
 production by T lym-
phocytes and NK cells.
 
16–18
 
 The receptor for IL-12 (IL-
12R) is composed of two distinct subunits, 
 
β
 
1 and 
 
β
 
2
 
19
 
(Fig. 3). Although the 
 
β
 
2 chain of the IL-12R is
expressed only in Th1 lymphocytes, the 
 
β
 
1 chain is
expressed in both Th1 and Th2 lymphocytes.
 
20
 
 The IL-
12R
 
β
 
1 chain does not contain any cytoplasmic tyrosine
residues, whereas the cytoplasmic region of the IL-
12R
 
β
 
2 chain contains three tyrosine residues. This sug-
gests that the 
 
β
 
2 subunit plays an important role in IL-12
signal transduction. Interleukin-12 induces activation of
specific members of the signal transducers and activa-
tors of transcription (Stat) family of transcription factors
and it has been shown that Stat4-deficient mice manifest
impaired production of IFN-
 
γ
 
21
 
 and the phenotype of the
IL-12-p40-deficient mouse is similar to that of the Stat4-
deficient mouse.
 
15
 
 Therefore, Stat4 is particularly impor-
tant. Interleukin-12 induces rapid tyrosine phosphoryla-
tion of Stat4 and the formation of nuclear complexes
capable of binding to DNA sequences, such as the
Stat4-binding site.
 
21,22
 
Interleukin-18 and IL-18R
 
A variety of biological functions have been associated
with human IL-18, including the induction of the pro-
liferation of activated T lymphocytes, enhancement of
NK cytotoxity, induction of the production of IFN-
 
γ
 
and granulocyte–macrophage colony stimulating factor
(GM-CSF), and promotion of a Th1 response.
 
2,23–25
 
 The
activity of IL-18 is via an IL-18R complex. This IL-18R
complex is composed of a binding chain termed IL-
18R
 
α
 
, a member of the IL-1R family previously identified
as the IL-1R-related proteins, and a signaling chain, also
a member of the IL-1R family. The IL-18R complex
recruits the IL-1R-activating kinase and tumor necrosis
factor (TNF)-associated factor 6, which phosphorylates
nuclear factor (NF)-
 
κ
 
B-inducing kinase, with subsequent
activation of NF-
 
κ
 
B
 
26–28
 
 (Fig. 4).
 
Fig. 3
 
Interleukin (IL)-12 sign-
aling. TYK2, tyrosine kinase 2;
JAK2, Janus kinase 2; STAT4,
signal transducers and activa-
tors of transcription 4; IFN, inter-
feron.
 
Fig. 4
 
Interleukin (IL)-18 signaling. IL-18R
 
α, IL-18Rβ, IL-18
receptor α and β chains, respectively; IKK-1, Ikk-2, IκBα kinases
1 and 2, respectively; NF-κB, nuclear factor-κB; NIK, NF-κB-
inducing kinase; TRAF-6, tumor necrosis factor receptor-associ-
ated factor 6; IRAK, IL-1 receptor-associated kinase.
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Interferon-γ production by IL-12 or IL-18 in 
atopy
We examined the production of IFN-γ in PBMC of atopic
patients and healthy controls following stimulation with
IL-12 or IL-18.10,11 The PBMC of non-atopic healthy
controls showed adequate IFN-γ production following
stimulation with either IL-12 or IL-18. Although the
concentrations of IFN-γ in IL-18-stimulated PBMC were
correlated with those of IL-12-stimulated PBMC in atopic
patients, there were cases showing different responses to
IL-12 and IL-18, as shown in Fig. 5. The production of
IFN-γ following stimulation with IL-12 (or IL-18) was
poor, but IL-18 (or IL-12) stimulation elicited detectable
IFN-γ production in some atopic patients. The discrep-
ancy in IFN-γ production following stimulation with IL-12
or IL-18 suggests a disturbance in the IL-12 or IL-18
signal cascade in these patients.
Role of mutations of the IL-12Rβ2 chain gene 
in atopy
Recently, it was shown that homozygous nonsense muta-
tion of the IL-12Rβ1 chain gene resulted in impairment
of immunity against Salmonella and mycobacteria.29
Moreover, IL-12Rβ1-knock out mice showed impaired
development of Th1.30 In a previous study,10 sequence
analysis of the cDNA of IL-12Rβ2 revealed three types of
distinct genetic mutations (2496del91, 1577 A to G
(R313G), 2799 A to G (H720R)) in some atopic patients
(Fig. 6). Reduced production of IFN-γ by PBMC follow-
ing stimulation with IL-12, but not IL-18, is associated
with heterozygous IL-12Rβ2 chain cDNA mutations in
atopic subjects. In these atopic patients, a heterozygous
IL-12Rβ2 chain cDNA mutation results in decreased
tyrosine phosphorylation of Stat4 and subsequently
reduced production of IFN-γ following stimulation with
IL-12. Such reduced production of IFN-γ could cause
insufficient suppression of accelerated IgE production in
B lymphocytes by IL-4, resulting in the elevation of serum
Fig. 5 Interferon (IFN)-γproduction in peripheral blood mono-
nuclear cells (PBMC) stimulated with interleukin (IL)-12 or IL-18
(see text for details).
Fig. 6 Interleukin (IL)-12 sign-
aling and mutations of IL-12
receptor β (IL-12Rβ) 2 chain
gene. R, arginine; G, glycine; H,
histidine; Y, tyrosine (2451 C
to T: by RNA editing); TYK2,
tyrosine kinase 2; JAK2, Janus
kinase 2; STAT4, signal trans-
ducers and activators of tran-
scription 4.
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IgE levels (Fig. 7). The 2496del91 mutation of IL-12Rβ2,
which is found all over the transmembrane portion,
causes premature termination. The heterozygous mis-
sense mutations, 1577 A to G (R313G) and 2799 A to
G (H720R), may lead to changes in the conformational
structure. Moreover, these heterozygous mutations may
play a role via a dominant negative effect. At least, these
patients with heterozygous mutations of IL-12Rβ2 chain
cDNA have not exhibited impairment of immunity
against Salmonella and mycobacteria.
The balance between IFN-γ-producing Th1 lympho-
cytes and proallergic Th2 lymphocytes is important.
Heterozyous mutations of IL-12β1 or β2 may result in
impairment of the downregulation (brake) of IgE pro-
duction, whereas homozygous mutations of IL-12β1 or
β2 may lead to an obvious impairment of Th1-type cell-
mediated immunity in addition to impairment of the
downregulation of IgE production. The results of our
study10 indicate that atopic diseases are caused, in part,
by impairment of the IL-12 signal cascade, which down-
regulates IgE production, and that the mutation of
Fig. 7 Suppression of IgE production of peripheral blood
mononuclear cells (PBMC; see text for details). The PBMC
(10–6 /mL) were cultured with Derf 1 (0.5 µg/mL; Asahi, Tokyo,
Japan) and interluekin (IL)-4 (500 U/mL; Genzyme, Cam-
bridge, MA, USA) in culture test tube for 14 days. Moreover,
interferon (IFN)-γ (100 U/mL) or IL-12 (5 IU/mL) was added to
these PBMC cultures. Culture supernatants were obtained after
the cultures. The concentration of IgE in culture supernatants
was measured by ELISA. Subject 1, an atopic patient without
mutations of the IL-12Rβ2 chain gene; subject 2, an atopic
patient with 91del of the IL-12Rβ2 chain gene; subject 3, an
atopic patient with a missense mutation of the IL-12Rβ2 chain
gene.
Fig. 8 (a) 950delCAG in interluekin (IL)-18 receptor α
(IL-18Rα) chain cDNA and (b) model of the ternary complex of
IL-18Rβ : IL-18 : IL-18Rα.
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the IL-12β2 chain gene is one of the causative genes
for atopy.
Role of mutation of the IL-18Rα chain gene in 
atopy
The IL-18Rα chain cDNA of atopic patients was
sequenced.11 We identified a three-base deletion of the
IL-18Rα chain cDNA (950delCAG), which was gener-
ated by alternative splicing, as determined on the basis
of genomic sequence data for the IL-18Rα chain gene
(Fig. 8). Peripheral blood mononuclear cells with the
predominant expression of 950delCAG significantly
showed reduced IFN-γ production after IL-18 stimula-
tion. There was a significant difference in the expression
pattern of the IL-18Rα chain transcript between atopic
patients and non-atopic controls. According to these
results, the dominant expression of the 950delCAG
transcript of IL-18Rα chain cDNA, which was associated
with reduced IFN-γ production following IL-18 stimula-
tion and high serum IgE levels, predisposes to some
atopic diseases.
Role of mutation of the IFN-γR1 chain gene in 
atopy
We identified a novel heterozygous single-nucleotide
substitution 1400 T to C (Leu467Pro) in the seventh
exon of the IFN-γR1 chain gene.31 This substitution was
detected in six of 89 allergic patients, but not in 72
non-allergic subjects. There was a difference in the
Leu467Pro frequency between allergic and non-allergic
subjects (P < 0.05). Serum IgE levels of allergic patients
with Leu467Pro were higher than those of non-allergic
Fig. 9 A new genetic classification of atopy and genetic ecologic medicine in allergy (designed by N Kondo, 2002). HLA-Pep-TCR,
human leukocyte antigen–peptide–T cell receptor; IL, interleukin; IFN, interferon; VDJ-Cε, variable diversity joining-ε constant
region; LT, leukotriene; R, receptor; APC, antigen-presenting cell; DH, delayed-type hypersensitivity; Eo, eosinophils.
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subjects (P < 0.001). These results suggest that Leu467Pro
in the IFN-γR1 chain gene is one of the candidate
susceptibility genes for atopic diseases.
GENETIC CLASSIFICATION OF ATOPY
Recently, mutations or genetic polymorphisms of several
genes, such as those encoding the Fc∈RIβ,5 IL-4Rα
subunit8 and IL-13,9 have been reported as the probable
causative genes of atopy, which is characterized by
enhanced IgE production. Based on these reports and
our results, we present a new genetic classification of
atopy in Fig. 9. There are four categories of genes
that control the expression of allergic disorders,
which include: (i) antigen recognition; (ii) IgE production
(downregulation = brake; and upregulation); (iii) the
production and release of mediators; and (iv) events on
target organs. In the near future, this genetic classi-
fication will facilitate the development of tailor-made
treatment.
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